HIV/AIDS Topics At Least 6000 People Thought to Be on HIV PrEP in San Francisco
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Friday, 03 June 2016 00:00
- Written by Liz Highleyman
New numbers from the city's largest pre-exposure prophylaxis (PrEP) programs, along with estimates from primary providers and other smaller sources, suggest that more than 6000 people in San Francisco are receiving or have received Truvada for HIV prevention, most of them gay and bisexual men.
Experimental HIV Vaccine to Enter Large Clinical Trial in South Africa
- Details
- Category: HIV Vaccines
- Published on Thursday, 26 May 2016 00:00
- Written by NIH
An investigational vaccine that showed promise in an earlier study will advance to a large-scale efficacy trial at 15 sites in South Africa, the U.S. National Institutes of Health (NIH) announced on May 18, marking HIV Vaccine Awareness Day. The new trial, HVTN 702, designed to determine if the vaccine is safe, well-tolerated, and effective at preventing HIV infection, is due to start this November, with results expected in 4 years.
BHIVA 2016: Which Men Stand to Benefit Most from PrEP?
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Tuesday, 03 May 2016 00:00
- Written by Michael Carter
New data from the PROUD pre-exposure prophylaxis (PrEP) study have identified the characteristics of the gay and other men who have sex with men who are most likely to benefit from PrEP, according to findings reported at the recent conference of the British HIV Association (BHIVA) in Manchester. Gay men with rectal sexually transmitted infections (STIs) and those who had unprotected receptive anal sex with more partners were most likely to benefit from PrEP.
U.S. Government Updates Guidelines for HIV Post-Exposure Prophylaxis
- Details
- Category: Post-exposure Prophylaxis (PEP)
- Published on Sunday, 08 May 2016 00:00
- Written by Liz Highleyman
The U.S. Centers for Disease Control and Prevention (CDC) and Department of Health and Human Services (DHHS) in April issued their latest guidelines for non-occupational post-exposure prophylaxis (PEP) for people potentially exposed to HIV through sex or shared injection equipment. The update includes new antiretrovirals approved since the last revision, with the preferred regimen now being raltegravir (Isentress) or dolutegravir (Tivicay) plus tenofovir/emtricitabine (the drugs in Truvada).
Study Sheds Light on Why Women Need More Truvada for HIV PrEP
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Wednesday, 30 March 2016 00:00
- Written by Liz Highleyman
Tenofovir and emtricitabine -- the drugs in the Truvada combination pill used for HIV pre-exposure prophylaxis (PrEP) -- reach higher levels in rectal compared with female genital tract tissue, and the rectum also contains fewer of the natural DNA building blocks that compete with the drugs, according to research published in the February 24 advance online edition of the Journal of Infectious Diseases.
More Articles...
- England's PrEP Policy in Disarray After National Health Service Turnaround
- NIAID To Fund Follow-Up Study of Dapivirine Vaginal Ring for HIV Prevention
- CROI 2016: High STI Rates Among Gay Men on PrEP Supports More Frequent Monitoring
- CROI 2016: Rapid Rise in PrEP Awareness in U.S. Gay Men, But Only 5% Have Used PrEP
Web Design and Development by